About: Shedding Light on the Effect of Natural Anti-Herpesvirus Alkaloids on SARS-CoV-2: A Treatment Option for COVID-19

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Shedding Light on the Effect of Natural Anti-Herpesvirus Alkaloids on SARS-CoV-2: A Treatment Option for COVID-19 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Shedding Light on the Effect of Natural Anti-Herpesvirus Alkaloids on SARS-CoV-2: A Treatment Option for COVID-19
Creator	Hassan, Sherif
Source	Medline; PMC
abstract	The whole world is currently facing an unseen enemy, called coronavirus disease 2019 (COVID-19), which is causing a global pandemic. This disease is caused by a novel single-stranded enveloped RNA virus, known as the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2). Although huge efforts are being made to produce effective therapies to combat this disease, it continues to be one of the greatest challenges in medicine. There is no doubt that herpesviruses are one of the most important viruses that infect humans and animals, and infections induced by these pathogens have developed into a great threat to public health. According to the currently available evidence, the correlation between herpesviruses and coronaviruses is limited to the induced complications following the infections. For instance, the inflammation that is induced at the sites of infection could tie these viruses to each other in a relationship. Another example, bovine herpesvirus 1, which is an important pathogen of cattle, can cause a severe respiratory infection; the same way in which SARS-CoV-2 affects humans. Considering the current circumstances related to the COVID-19 crisis, this editorial paper, which belongs to the Special Issue “Recent Advances in Herpesviruses Research: What’s in the Pipeline?” aims to draw attention to some natural anti-herpesvirus alkaloid compounds, which have recently been proven to have excellent inhibitory efficacy against SARS-CoV-2 replication. Thus, this special focus is an attempt to hunt down various treatment options to combat COVID-19 based on repurposing drugs that are known to have multiple antiviral properties, including against herpesvirus.
has issue date	2020-04-23(xsd:dateTime)
bibo:doi	10.3390/v12040476
bibo:pmid	32340120
has license	cc-by
sha1sum (hex)	4f1c4aa104493164c6b5ac0f7e0cec1e8d9e226a
schema:url	https://doi.org/10.3390/v12040476
resource representing a document's title	Shedding Light on the Effect of Natural Anti-Herpesvirus Alkaloids on SARS-CoV-2: A Treatment Option for COVID-19
has PubMed Central identifier	PMC7232216
has PubMed identifier	32340120
schema:publication	Viruses
resource representing a document's body	covid:4f1c4aa104493164c6b5ac0f7e0cec1e8d9e226a#body_text
is schema:about of	named entity 'COVID-19' named entity 'Natural' named entity 'Alkaloids' named entity 'preclinical studies' named entity 'Viruses' named entity 'cytomegalovirus' named entity 'omacetaxine mepesuccinate' named entity 'SARS-CoV-2' named entity 'COVID' named entity 'alkaloids' named entity 'review article' named entity 'varicella-zoster virus' named entity 'herpesvirus' named entity 'accelerated phase' named entity 'Homoharringtonine' named entity 'amoebiasis' named entity 'antiviral' named entity 'COVID' named entity 'preclinical' named entity 'natural products' named entity 'emetine' named entity 'FDA' named entity 'herpes simplex virus' named entity 'herpes' named entity 'Viruses' named entity 'pseudorabies virus' named entity 'mechanisms of action' named entity 'cephalotaxus' named entity 'herpes simplex viruses' named entity 'Viruses' named entity 'chronic myeloid leukemia' named entity 'alkaloid' named entity 'Emetine' named entity 'coronavirus' named entity 'cardiotoxicity' named entity 'alkaloid' named entity 'bioactive' named entity 'review article' named entity 'COVID' named entity 'bovine herpesvirus 1' named entity 'Herpesviruses' named entity 'protein synthesis inhibitor' named entity 'antiviral activity' named entity 'SARS-CoV-2' named entity 'herpesviruses' named entity 'emetine' named entity '2.55' named entity 'protein synthesis inhibitor' named entity 'SARS-CoV-2' named entity 'Cephalotaxus' named entity 'alkaloids' named entity 'herpes simplex virus 2' named entity 'macromolecules' named entity 'Herpesviruses' named entity 'SARS-CoV-2' named entity 'herpes simplex virus 1' named entity 'Emetine' named entity 'bioactivity' named entity 'U.S. Food and Drug Administration' named entity 'homoharringtonine' named entity 'genus' named entity 'COVID' named entity 'viruses' named entity 'CURRENTLY' named entity 'TREATMENT OPTION' named entity 'VIRUSES' named entity 'SARS-CoV-2' named entity 'Herpesvirus' named entity 'viruses' named entity 'Option' named entity 'Light' named entity 'Alkaloids' named entity 'SARS-CoV-2' named entity 'EDITORIAL' named entity 'HERPESVIRUS' named entity 'NATURAL' named entity 'WORLD' named entity 'SARS-COV-2' named entity 'LIGHT' named entity 'ALKALOIDS' named entity 'COVID-19'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software